Atyr Pharma Inc (NASDAQ: ATYR) on Monday, plunged -7.51% from the previous trading day, before settling in for the closing price of $3.86. Within the past 52 weeks, ATYR’s price has moved between $1.42 and $4.22.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 545.22% over the past five years. The company achieved an average annual earnings per share of 2.84%. With a float of $81.96 million, this company’s outstanding shares have now reached $83.94 million.
Let’s look at the performance matrix of the company that is accounted for 59 employees. In terms of profitability, gross margin is -563.83%, operating margin of -28958.72%, and the pretax margin is -27155.32%.
Atyr Pharma Inc (ATYR) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Atyr Pharma Inc is 2.36%, while institutional ownership is 63.08%. The most recent insider transaction that took place on Jul 24 ’24, was worth 101,038. In this transaction Director of this company bought 52,300 shares at a rate of $1.93, taking the stock ownership to the 413,023 shares. Before that another transaction happened on Jul 22 ’24, when Company’s Director bought 41,052 for $1.74, making the entire transaction worth $71,500. This insider now owns 354,075 shares in total.
Atyr Pharma Inc (ATYR) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.24 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.84% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 13.72% during the next five years compared to 43.36% growth over the previous five years of trading.
Atyr Pharma Inc (NASDAQ: ATYR) Trading Performance Indicators
Atyr Pharma Inc (ATYR) is currently performing well based on its current performance indicators. A quick ratio of 5.41 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1302.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.94, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -0.81 in one year’s time.
Technical Analysis of Atyr Pharma Inc (ATYR)
Atyr Pharma Inc (NASDAQ: ATYR) saw its 5-day average volume 0.69 million, a negative change from its year-to-date volume of 0.84 million. As of the previous 9 days, the stock’s Stochastic %D was 68.53%. Additionally, its Average True Range was 0.26.
During the past 100 days, Atyr Pharma Inc’s (ATYR) raw stochastic average was set at 74.36%, which indicates a significant increase from 51.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.73% in the past 14 days, which was lower than the 71.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.44, while its 200-day Moving Average is $2.37. Nevertheless, the first resistance level for the watch stands at $3.67 in the near term. At $3.78, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.95. If the price goes on to break the first support level at $3.40, it is likely to go to the next support level at $3.23. Assuming the price breaks the second support level, the third support level stands at $3.12.
Atyr Pharma Inc (NASDAQ: ATYR) Key Stats
Market capitalization of the company is 299.68 million based on 83,942K outstanding shares. Right now, sales total 350 K and income totals -50,390 K. The company made 0 K in profit during its latest quarter, and -16,310 K in sales during its previous quarter.
